Akero Therapeutics, Inc.

Equities

AKRO

US00973Y1082

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
19.74 ^USD	+4.28%		-4.91%	-15.46%

Mar. 08	Akero Therapeutics Raises $367 Million From Share Offering	MT
Mar. 07	Akero Therapeutics, Inc. Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology	CI

Health Care Down on Growth Doubts -- Health Care Roundup

March 04, 2024 at 05:59 pm EST

Health-care companies ticked down as traders hedged their bets on the outlook for growth in the sector.

Shares of the Wuxi family of biotech and research companies, listed both in Shanghai and Hong Kong, rose sharply on receding worries about potential U.S. sanctions.

Akero Therapeutics rose after promising data on its treatment of a serious liver condition known as MASH. Shares of Akero were under pressure after Eli Lilly released trial results that seemed to cast doubt over the future of such products.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

03-04-24 1758ET

Latest news about Akero Therapeutics, Inc.

Akero Therapeutics Raises $367 Million From Share Offering	Mar. 08	MT
Akero Therapeutics, Inc. Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology	Mar. 07	CI
Akero Therapeutics Insider Sold Shares Worth $732,727, According to a Recent SEC Filing	Mar. 07	MT
Akero Therapeutics Insider Sold Shares Worth $2,465,063, According to a Recent SEC Filing	Mar. 07	MT
UBS Adjusts Akero Therapeutics Price Target to $42 From $39, Maintains Buy Rating	Mar. 05	MT
HC Wainwright Raises Price Target on Akero Therapeutics to $50 From $43, Maintains Buy Rating	Mar. 05	MT
Health Care Down on Growth Doubts -- Health Care Roundup	Mar. 04	DJ
Akero Therapeutics Proposes $300 Million Common Stock Offering -- Stock Down After Hours	Mar. 04	MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Monday	Mar. 04	MT
Sector Update: Health Care	Mar. 04	MT
US Equity Futures Turn Cautiously Lower Pre-Bell as Investors Eye Powell Testimony	Mar. 04	MT
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell as Traders Hope for Clues to Timing of Rate Cuts	Mar. 04	MT
Top Premarket Gainers	Mar. 04	MT
Transcript : Akero Therapeutics, Inc. - Special Call	Mar. 04
Akero Therapeutics Reports Greater Fibrosis Improvement in Efruxifermin Phase 2b Study; Shares Gain Pre-Bell	Mar. 04	MT
Akero's lead drug helps improve scarring in fatty liver disease patients	Mar. 04	RE
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study	Mar. 04	CI
Akero Therapeutics' Q4 Loss Widens; Cash Expected to Fund Operations Into 2026	Feb. 29	MT
Akero Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Akero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Transcript : Akero Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 09:45 AM	Jan. 08
Akero Therapeutics, Inc. Announces First Patients Dosed in Efruxifermin Phase 3 Synchrony Program	Dec. 18	CI
Akero Therapeutics Insider Bought Shares Worth $1,982,940, According to a Recent SEC Filing	Dec. 12	MT
Akero Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
UBS Adjusts Akero Therapeutics Price Target to $39 From $83, Maintains Buy Rating	23-10-12	MT

Chart Akero Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing phase IIb SYMMETRY, phase III SYNCHRONY Histology, and phase III SYNCHRONY real-world studies. The phase III SYNCHRONY program builds on the results of two phase IIb clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. EFX is designed to offer convenient once-weekly dosing.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

19.74 USD

Average target price

47.5 USD

Spread / Average Target

+140.63%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AKERO THERAPEUTICS, INC.	-15.46%	1.37B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs